Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.40 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.40 |
| ▸ | FLT1 | P17948 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31161002 | 0.81 | KDM4E (0.50) | SMN1; SMN2ALDH1A1POLBHPGDKDM4E | |
| SCHEMBL9268117 | 0.81 | HPGD (0.62) | SMN1; SMN2ALDH1A1HPGDKDM4ECYP3A4 | |
| SCHEMBL14373412 | 0.80 | HPGD (0.45) | SMN1; SMN2ALDH1A1POLBHPGDKDM4E | |
| SCHEMBL7447850 | 0.79 | SLC6A2 (0.48) | PKMSMN1; SMN2ALDH1A1ABCB1ABCC1 | |
| SCHEMBL1667720 | 0.79 | SIRT6 (0.56) | PKMSMN1; SMN2ALDH1A1POLBMAPT | |
| SCHEMBL28444583 | 0.77 | APEX1 (0.48) | SMN1; SMN2ALDH1A1HPGDKDM4ENPC1 | |
| SCHEMBL21296309 | 0.76 | HPGD (0.63) | PKMSMN1; SMN2POLBHPGDNPC1 | |
| SCHEMBL22278705 | 0.76 | LMNA (0.55) | PKMALDH1A1KDM4ENPC1MAPT | |
| SCHEMBL23861174 | 0.75 | PDGFRB (0.56) | PKMSMN1; SMN2ALDH1A1POLBKDM4E | |
| SCHEMBL22324639 | 0.75 | KDM4E (0.55) | PKMSMN1; SMN2ALDH1A1POLBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3280707-B1 | BICYCLIC QUINAZOLINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2023-12-20 | — | — | EP | disclosed |
| US-20200317624-A1 | BICYCLIC QUINAZOLINONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-10-08 | — | — | US | disclosed |
| US-20200317624-A1 | BICYCLIC QUINAZOLINONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-10-08 | — | — | US | disclosed |
| US-10676446-B2 | Bicyclic quinazolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-10676446-B2 | Bicyclic quinazolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2020-06-09 | — | — | US | disclosed |
| EP-3280707-A1 | BICYCLIC QUINAZOLINONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2018-02-14 | — | — | EP | disclosed |
| US-20180029996-A1 | BICYCLIC QUINAZOLINONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-02-01 | — | — | US | disclosed |
| US-20180029996-A1 | BICYCLIC QUINAZOLINONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-02-01 | — | — | US | disclosed |
| US-20180029996-A1 | BICYCLIC QUINAZOLINONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-02-01 | — | — | US | disclosed |
| WO-2016162390-A1 | BICYCLIC QUINAZOLINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2016-10-13 | — | — | WO | disclosed |
| WO-2016162390-A1 | BICYCLIC QUINAZOLINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2016-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200317624-A1 | BICYCLIC QUINAZOLINONE DERIVATIVES | BRD4, BICRA, NDUFC2 | PKM 2764/4885SMN1; SMN2 2930/4885ALDH1A1 975/4885 |
| US-20180029996-A1 | BICYCLIC QUINAZOLINONE DERIVATIVES | BRD4, BICRA, NDUFC2 | PKM 2764/4885SMN1; SMN2 2930/4885ALDH1A1 975/4885 |
| US-10676446-B2 | Bicyclic quinazolinone derivatives | BRD4, BICRA, NDUFC2 | PKM 2764/4885SMN1; SMN2 2930/4885ALDH1A1 975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.